Microbiological evaluation of a new growth-based approach for rapid detection of methicillin-resistant Staphylococcus aureus by von Eiff, Christof et al.
Microbiological evaluation of a new growth-based approach for rapid
detection of methicillin-resistant Staphylococcus aureus
Christof von Eiff1*, Dominik Maas1, Gunnar Sander1, Alexander W. Friedrich2,
Georg Peters1 and Karsten Becker1
1Institute of Medical Microbiology, University Hospital of Mu ¨nster, Domagkstr. 10, 48149 Mu ¨nster, Germany;
2Institute for Hygiene, University Hospital of Mu ¨nster, Robert-Koch-Str. 41, 48149 Mu ¨nster, Germany
Received 18 January 2008; returned 12 February 2008; revised 26 February 2008; accepted 26 February 2008
Objectives: Recently, a rapid screening tool for methicillin-resistant Staphylococcus aureus (MRSA)
has been introduced that applies a novel detection technology allowing the rapid presence or absence
of MRSA to be determined from an enrichment broth after only a few hours of incubation. To evaluate
the reliability of this new assay to successfully detect MRSA strains of different origin and clonality,
well-characterized S. aureus strains were tested in this study.
Methods: More than 700 methicillin-susceptible and methicillin-resistant strains covering >90% of all
registered European MRSA spa types within the SeqNet network were studied.
Results: All 513 MRSA strains tested were recognized as methicillin-resistant: among these, 96 MRSA
strains were from an institutional collection, each presenting a unique spa type. None of the 211 methi-
cillin-susceptible strains were detected as positive.
Conclusions: The new growth-based rapid MRSA assay was shown to detect without exception all
MRSA strains of large collections of strains comprising highly diverse genetic backgrounds, indicating
that such a phenotypic test might be potentially more likely to cope with new strains.
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Introduction
The increasing numbers of multidrug-resistant Gram-positive
pathogens have generated worldwide concern in the medical
community. In particular, methicillin-resistant Staphylococcus
aureus (MRSA) is a major cause of disease and healthcare
expenditures in almost every continent. The emergence and
spread of MRSA has been shown to be associated with both
hospital- and community-acquired infections. Effective treatment
options for these infections are limited and the situation may
become more severe soon. For these reasons, a proactive man-
agement of MRSA in healthcare facilities is needed.
1,2
Active screening and compliance to appropriate infection
control activities have been shown to play an important role in
the control of MRSA.
1 Rapid diagnostic tests have the potential
to make efforts even more effective. Thus, infection prevention
has taken a step forward with the introduction of various tests
for rapid identiﬁcation of MRSA carriers.
1,2
In 2006, a new rapid method based on a novel biolumines-
cence detection technology for the rapid detection of MRSA
directly from specimens was published.
3 An improved version of
this assay, the 3MTM BacLiteTM Rapid MRSA Test (3M
Company, Maplewood, MN, USA), was recently introduced,
which allows the presence or absence of MRSA to be deter-
mined within 5 h. Although the clinical performance has been
previously analysed,
4,5 so far no data are available on the detec-
tion of MRSA strains with highly diverse genetic backgrounds.
The aim of this study was to assess the reliability of this
assay to successfully detect MRSA strains circulating currently
in Germany and other parts of Europe on the basis of several
well-characterized S. aureus strain collections. For this
purpose, S. aureus strains of different origin and clonality com-
prising 724 methicillin-susceptible and methicillin-resistant
strains comprising .90% of all registered European MRSA
spa types within the SeqNet network (www.SeqNet.org) were
tested in this study.
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All staphylococcal strains were freshly isolated from clinical
material at the University of Mu ¨nster or during the course of various
multicenter studies. One hundred and sixty-four strains isolated
from patients with S. aureus bacteraemia (including 12 MRSA
strains) as well as 50 isolates from the anterior nares of patients who
did not subsequently develop S. aureus bacteraemia in a subsequent
observation period (4 MRSA strains), were included into this study.
Apart from 28 isolates from 14 patients (S. aureus ﬁrst recovered
from the anterior nares and subsequently from blood, one infected
with MRSA), only one isolate per patient was tested. In addition, 96
MRSA strains, each presenting a unique spa type, were selected
from our institutional collection (Table 1). Furthermore, four
hundred MRSA isolates were collected during the course of a recent
multicenter study, also including community-acquired MRSA. In
total, the 724 S. aureus strains tested comprised 211 methicillin-
susceptible S. aureus (MSSA) and 513 MRSA strains.
If the biochemical identiﬁcation of staphylococcal isolates using
the ATB 32 Staph gallery (bioMe ´rieux, Marcy l’E ´toile, France) was
ambiguous or categorized as unacceptable, partial 16S rRNA gene
and RNA polymerase B (rpoB) gene sequencing was performed as
described previously.
6 Isolates were conﬁrmed to be methicillin-
resistant by detection of the mecA gene.
To determine the clonal lineages of MRSA strains, the x region
of the spa gene was ampliﬁed by PCR with primers 1095F
(50-AGACGATCCTTCGGTGAGC-30) and 1517R (50-GCTTTTG
CAATGTCATTTACTG-30). DNA sequences were obtained with an
ABI 377 sequencer (Applied Biosystems, Foster City, CA, USA).
spa types were determined using the Ridom StaphType software
version 1.3 (Ridom GmbH, Wu ¨rzburg, Germany), and spa clonal
complexes (spa-CCs) were assigned by using the BURP algorithm.
7
The 3MTM BacLiteTM Rapid MRSA Test is a novel culture-based
test for the detection of MRSA performed on a semi-automated
system comprising a sample processor and a luminometer. The
assay consists of three successive selectivity steps: selective enrich-
ment in a proprietary broth containing cefoxitin (2 mg/L) and colis-
tin (50 mg/L), immuno-magnetic extraction using a highly speciﬁc
anti-S. aureus monoclonal antibody and selective lysis using lysosta-
phin. The selectivity steps are followed by a detection step using a
highly sensitive cell marker, adenylate kinase (AK). AK is an essen-
tial enzyme found in all living cells, which regulates energy pro-
vision by catalysing the equilibrium reaction ATP þ AMP ¼ 2 ADP.
By supplying a continual source of puriﬁed ADP, this assay drives
the AK reaction to generate up to 40 000 ATP molecules per min.
These ampliﬁed levels of ATP are measured using the luminometer
supplied with the system.
For the present study, test isolates were streaked on sheep blood
agar plates and grown at 378C to conﬁrm purity. For each isolate,
one to three colonies were picked and suspended in sterile saline
(0.9%) to achieve a turbidity equivalent to that of a 0.5 McFarland
standard. Usually, 43 isolates were processed in each run. The
3MTM BacLiteTM Rapid MRSA Test was performed according to
the instructions of the manufacturer. In brief, 10 mLo fe a c hp r e -
pared bacterial suspension was transferred into a vial containing
1 mL of selective enrichment broth. Vials were incubated at 378C
for 2 h before 150 mL aliquots of each test sample were transferred
into two adjacent wells of a 96-well assay plate, each containing
20 mL of capture reagent. MRSA cells bound to the monoclonal
antibody on the capture reagent were then extracted from the sample
matrix using the sample processor and concentrated in 100 mLo f
broth. One well for each sample was processed automatically for a
baseline signal (T0) in the BacLite luminometer. After a further
incubation period of 2 h at 378C, the second well for each sample
was processed in the same way (T2 reading). Results are expressed
in relative light units and interpreted as either a positive or negative
screen result by a software embedded algorithm. Positive and nega-
tive controls as well as reagent and broth controls were included in
each test run. A run took  5 h with a total hands-on time of 45–
50 min (,1.5 min per tested isolate).
Results and discussion
Analysing a total of 724 S. aureus strains, all 513 MRSA strains
tested were recognized as MRSA, whereas none of the 211
MSSA strains was detected positive by the 3MTM BacLiteTM
Rapid MRSA Test. These results are particularly impressive as
the institutional MRSA strain collection used in this study rep-
resents more than 90 different spa types covering .90% of all
registered European MRSA spa types within the SeqNet
network (Table 1). Beside several singletons, the MRSA
enrolled in this study were grouped into eight spa clonal com-
plexes (Table 1). Thus, a very large number of MRSA strains
with different genetic backgrounds were recognized as MRSA
using this novel method.
Table 1. Grouping of spa types tested in this study into spa clonal
complexes (spa-CCs)
spa-CC
a spa types
b Putative MLST types
c
001 t001, t002, t003, t010,
t035, t039, t041, t045,
t055, t057, t066, t105,
t106, t109, t110, t143,
t149, t151, t264, t265,
t422, t820, t892, t1018
ST-5, ST-45, ST-46,
ST-222, ST-225,
ST-228, ST-231,
ST-111, ST-228
004 t004, t028, t029, t033,
t040, t043, t061, t065,
t141, t142, t266, t911
ST-45, ST-45, ST-46
015 t015, t031, t069, t073,
t102, t116, t133
ST-45
024 t008, t009, t024, t036,
t051, t052, t068, t113,
t115, t139, t146, t243,
t305
ST-8, ST-235, ST-247,
ST-250, ST-254,
ST-247, ST-250
032 t005, t022, t032, t107,
t290, t379, t432, t794
ST-22, ST-23, ST-60
037 t011, t030, t037, t047,
t108, t135, t137, t138
ST-30, ST-239, ST-240,
ST-241, ST-246
038 t038, t161, t247 ST-45
044 t042, t044, t131 ST-80
Singletons t012, t091, t101, t104,
t163, t321, t372, t417,
t431, t907
ST-7, ST-30, ST-22
aNaming of spa-CC was derived from the group founder.
bt026, t103, t111, t132, t145, t282, t322 and t1007 were excluded from deter-
mination of the spa-CCs due to low number of repeats.
cPutative MLST types were taken from the public SeqNet.org spa server
database.
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faced with alarming rates of infections caused by MRSA.
Continuous spread of these pathogens requires efﬁcient strategies
for infection control. Early identiﬁcation of MRSA carriers
among hospitalized patients is crucial to prevent its spread.
1
Therefore, rapid availability of laboratory results is of utmost
importance. However, conventional screening methods require
prolonged incubation and conﬁrmatory testing. During this time,
MRSA-negative patients may be held in unnecessary isolation,
whereas unidentiﬁed MRSA-positive individuals remain a
hidden reservoir for cross-infection. A rapid negative result
should allow more effective use of hospital isolation resources,
whereas a rapid positive result should help reduce the spread of
the infection and MRSA infection rates.
2
In the past few years, several in-house and commercial rapid
MRSA assays based on molecular techniques have been intro-
duced for the detection of this pathogen directly from the speci-
men, mostly from the anterior nares. The ﬁrst molecular assays
developed were based on the detection of an S. aureus-speciﬁc
sequence and the mecA gene, which encodes methicillin resist-
ance.
8 These tests are difﬁcult to use for the direct detection of
MRSA from non-sterile specimens, such as nasal samples,
because of the likely co-presence of MSSA and methicillin-
resistant coagulase-negative staphylococci.
9 In a setting of low
prevalence of MRSA, a molecular test targeting the mecA and
an S. aureus-speciﬁc gene in parallel applied directly to clinical
specimens would result in a high number of false positives and
unacceptable performance.
9
This technical limitation has been overcome in some assays,
by linking detection of the presence of the mecA gene with
detection of the neighbouring chromosome-borne orfX gene.
10,11
In that approach, regions near the integration site of SCCmec
were targeted as surrogate markers instead of the mecA gene
itself. However, these ﬂanking regions are known to be more
heterogeneous than assumed so far.
10 Thus, false-negative
results due to variations within the primer binding sites may
occur. Moreover, false-positive results due to the detection of
DNA from non-viable MRSA, deletions or replacement of the
mec region in vivo or ‘ghost sequences’ such as partial SCCmec
sequences in MSSA can occur, albeit their incidence in the
routine clinical setting is as yet unclear.
12 Despite the technical
improvements in recent molecular-based assays, their high costs
and relatively high operator skill requirement remain obstacles to
their widespread routine use.
The ability of a test to detect a broad range of MRSA clones
is particularly important for an assay that may be used across a
wide geographic region as tests with gaps in detection could
potentially ‘select out’ strains whose spread would be
uncontrolled.
Beside a variety of method-inherent limitations, rapid
DNA-based methods amplify the nucleic acid and not the organ-
ism, which means the MRSA strain is unavailable for further
characterization, such as determination of the resistance proﬁle
and strain typing. In contrast, applying the rapid growth-based
assay tested here, any further examinations to characterize the
respective strains will be possible from the enrichment broth.
For the 3MTM BacLiteTM Rapid MRSA Test, a diagnostic
sensitivity of 94.6% and diagnostic speciﬁcity of 96.9% for
nasal screening swabs and 95.9% sensitivity and 88.8% speci-
ﬁcity for groin screening swabs, respectively, have been
reported.
4,5 The analytical limit of detection of the assay was
shown to be  94 cfu (3MTM BacLiteTM Rapid MRSA Test,
Instructions for Use).
4,5
Here, the new growth-based rapid MRSA assay was shown to
detect without exception all MRSA strains of large collections
of strains comprising highly diverse genetic backgrounds. Such
a phenotypic test might be potentially more likely to cope with
new strains. Further studies are warranted to evaluate this
method using clinical specimens.
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